Overview Request Sample Pages Request Customization Download PDF
You are viewing: US Gene Editing Market analysis
Part of: Gene Editing Market (Global)

The US Gene Editing Market was valued at $643.3 Million in 2024 and projected to reach to $1026.7 Million by 2029, representing a compound annual growth rate of 9.8%. The US gene editing market is positioned for sustained expansion through 2029, driven by increasing FDA approvals of CRISPR-based and alternative gene editing therapies.

US Gene Editing Market (2024-2029) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

US Gene Editing Market Trends and Insights

  • The US leads global adoption of gene editing technologies, driven by substantial investments in research and development, a strong regulatory framework, and increasing clinical applications across therapeutic areas.
  • The US market benefits from the presence of major biotechnology hubs, advanced healthcare infrastructure, and significant venture capital funding supporting innovation in CRISPR, base editing, and prime editing platforms. In the US, the gene editing market is accelerating due to rising prevalence of genetic disorders, growing approval of gene-edited therapeutics, and expanding applications in oncology and rare diseases.
  • The US regulatory environment, particularly FDA guidance on gene editing therapies, has created a favorable pathway for commercialization.
  • By 2029, the US market is expected to capture a substantial share of global gene editing revenues, reflecting the country's leadership in precision medicine and biotechnology innovation..

Key Market Statistics

  • CAGR (2024-2029) 9.8% CAGR
  • Market Size, 2024 ~USD 643.3 Million
  • Forecast, 2029 ~USD 1026.7 Million
  • Country US

US Gene Editing Market Overview

Market Valuation :

The US gene editing market is valued at $643.3 million in 2024, with projections reaching $1,026.7 million by 2029, representing a robust 9.8% CAGR over the forecast period.

R&D Investment Leadership :

The US dominates global gene editing innovation through substantial government and private sector R&D investments, supported by NIH funding, venture capital, and pharmaceutical company commitments to therapeutic development.

Regulatory Advancement :

The FDA's established regulatory pathways for gene editing therapies, including breakthrough designation programs, accelerate clinical development and market entry for innovative treatments in the US.

Therapeutic Expansion :

US clinical applications span oncology, rare genetic disorders, cardiovascular diseases, and immunotherapy, with multiple candidates in late-stage trials driving near-term commercialization opportunities.

US Gene Editing Market Dynamics

  • Major pharmaceutical and biotech companies are scaling manufacturing capabilities and expanding clinical pipelines, while academic institutions continue advancing foundational research.
  • Healthcare providers are integrating gene editing solutions into treatment protocols, particularly for previously untreatable genetic conditions. Key growth catalysts include rising healthcare spending on precision medicine, growing patient awareness, and strategic partnerships between biotech firms and established pharmaceutical companies.
  • Reimbursement frameworks are evolving to support gene editing therapies, though cost-effectiveness remains a consideration.
  • The US market will likely see consolidation among smaller biotech firms and increased competition from international players seeking market access..

Related Ecosystem

Key Takeaways

  • The US gene editing market is valued at $643.3 million in 2024 and will reach $1,026.7 million by 2029, representing a 9.8% CAGR.
  • The US dominates global gene editing adoption through advanced regulatory frameworks, substantial R&D investment, and a robust biotechnology ecosystem.
  • Clinical approvals and expanding therapeutic applications in rare diseases and oncology are driving US market growth through 2029.
  • The US market leadership is supported by venture capital funding, academic research institutions, and FDA-enabled pathways for gene-edited therapeutics.

Gene Editing Market Report Scope

Report Metric Details
Base Year 2024
Fastest Growing Segment CROS & CDMOS (End User)
Forecast Period 2024–2029
Growth Rate CAGR of 10.2% from 2024 to 2029
Largest Segment PRODUCTS (Offering)
Market Size Base Year (Billions) ~USD 4.67 (2024)
Revenue Forecast (Billions) ~USD 7.59 (2029)
Segments Covered Offering, Type, Technique, Technology, Application, End User

US Gene Editing Market Report Segmentation

6 segment dimensions are covered across the global market.

By Offering

  • Products
  • Services

By Type

  • Cell Line Development & Engineering
  • Gene Editing Kits
  • Gene Editing Libraries
  • Gene Editing Reagents
  • Grna Synthesis & Vector Construction
  • Library Construction & Screening
  • Other Services
  • Reagents & Consumables
  • Software & Systems

By Technique

  • Gene Silencing
  • Knock-In
  • Knock-Out
  • Other Techniques

By Technology

  • Antisense
  • Base Editing
  • Crispr
  • Other Technologies
  • Rnai
  • Talens
  • Zfns

By Application

  • Cell Line Engineering
  • Drug Discovery & Development
  • Genome Editing
  • Other Applications

By End User

  • Academic & Research Institutes
  • Cros & Cdmos
  • Other End Users
  • Pharmaceutical & Biotechnology Companies

US: GENE EDITING SERVICES MARKET, BY END USER, 2022–2029

Segment20222023202420252026202720282029CAGR (%)
ACADEMIC & RESEARCH INSTITUTES199.4186201.6221.6244.1268.7296326.910.2
CROS & CDMOS43.742.948.856.264.674.18597.414.8
OTHER END USERS106.697.2102.9110.4118.6127.4136.8147.27.4
PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES290.5269.4290316.7346.5379414.9455.19.4
TOTAL640.3595.5643.3704.9773.9849.1932.71026.79.8

US: GENE EDITING PRODUCTS MARKET, BY END USER, 2022–2029

Segment20222023202420252026202720282029CAGR (%)
ACADEMIC & RESEARCH INSTITUTES421.7395.8402.8435.2471.1509.8552.4599.88.3
CROS & CDMOS197.2187.7193.5211.8232.2254.4279306.69.6
OTHER END USERS168152.5149.9156.4163.4170.4177.7185.64.4
PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES565.1527532.8572615.3661.6712.3768.57.6
TOTAL1351.91262.912791375.414821596.31721.41860.67.8

Target Audience

  • Pharmaceutical & Biotech Executives : Strategic leaders need US market data to guide R&D investment allocation, clinical trial planning, and go-to-market strategies for gene editing therapies targeting American patients and healthcare systems.
  • Investment & Venture Capital Firms : Investors require detailed US market forecasts, competitive landscapes, and funding trends to identify high-potential gene editing startups and biotech companies for portfolio allocation and exit planning.
  • Healthcare Providers & Hospital Systems : Hospital administrators and clinical leaders need market insights to evaluate gene editing therapy adoption, budget planning, and integration into treatment protocols for US patient populations.
  • Regulatory & Policy Advisors : Regulatory consultants and policy makers require US-specific market data to inform FDA guidance development, reimbursement frameworks, and healthcare policy decisions affecting gene editing accessibility.
  • Market Research & Consulting Firms : Research professionals need comprehensive US market data to support client advisory services, competitive benchmarking, and strategic recommendations for healthcare and life sciences organizations.

Key Companies in the US Gene Editing Market

CompanyHQOwnershipStrongest segments
EPPENDORF AGGermanyPrivate CompanyLiquid handling (pipettes, dispensers, automated systems),Separation & instrumentation (centrifuges, PCR cyclers, ULT freezers),Consumables (tubes, tips, plates, single-use bioreactors),
ILLUMINA INCUnited StatesPublic CompanySequencing instruments,Sequencing consumables (reagents, flow cells, library prep, WGS and targeted kits),Array-based instruments and consumables,
CALYXTUnited StatesPublic CompanyRTDS / Trait Machine platform services,Licensed gene-edited traits (royalties and access fees),Collaborative R&D and proof-of-concept projects,
MAXCYTE, INCUnited StatesPublic CompanyExPERT GTx and VLx (therapeutic-scale instruments),ExPERT STx and ATx (discovery and development instruments),Disposable processing assemblies and consumables,
BECKMAN COULTERUnited StatesPrivate CompanyClinical diagnostics analyzers and reagents (chemistry, immunoassay, hematology, urinalysis, hemostasis, clinical flow cytometry),Research and discovery systems (flow cytometry, centrifugation, liquid handling, genomics and single-cell tools),Industrial and particle characterization instruments,
TAKEDA PHARMACEUTICAL COMPANYJapanPublic CompanyGastroenterology (Entyvio, Takecab/Vocinti, EOHILIA),Rare Diseases & Plasma-Derived Therapies (Takhzyro, Advate, ADZYNMA, Gammagard, Hyqvia, Cuvitru, Flexbumin),Oncology (Adcetris, Ninlaro, Iclusig, FRUZAQLA, Alunbrig, Leuplin/Enantone),
DANAHER CORPORATIONUnited StatesPublic CompanyBiotechnology (bioprocessing and single-use solutions),Life Sciences (tools, genomics, and imaging),Diagnostics (clinical instruments and consumables),
REVVITY, INC.United StatesPublic CompanyDiagnostics assays and instruments (prenatal, neonatal, infectious disease, autoimmunity),Life science reagents and consumables (immunology, cell biology, genomics),Instruments, imaging, and detection platforms,
THERMO FISHER SCIENTIFIC INC.United StatesPublic CompanyLife Sciences Solutions,Analytical Instruments,Specialty Diagnostics,
MERCK KGAAGermanyPublic CompanyLife Science (reagents, consumables, bioprocessing, CDMO/testing services),Healthcare (prescription drugs and biopharmaceuticals),Electronics (semiconductor and display materials, specialty gases, equipment),
GENSCRIPTHong KongPublic CompanyLife Science Services and Products,Biologics Development Services,Industrial Synthetic Biology Products,
AGILENT TECHNOLOGIES, INC.United StatesPublic CompanyLife Sciences and Diagnostics Markets,Agilent CrossLab,Applied Markets,
LONZASwitzerlandPublic CompanyIntegrated Biologics,Advanced Synthesis (small molecules, ADCs, HPAPIs),Specialized Modalities (cell & gene, microbial, bioscience, mRNA),
SANGAMO THERAPEUTICSUnited StatesPublic CompanyHemophilia A gene therapy collaborations (SB-525 / giroctocogene fitelparvovec),Fabry and other AAV gene therapy programs (ST-920 and related),Genetically modified cell therapy (TX200, kidney transplant),
PRECISION BIOSCIENCESUnited StatesPublic CompanyARCUS platform collaborations and licensing,In vivo HBV and liver disease programs (PBGENE-HBV, iECURE-OTC),Neuromuscular and mitochondrial programs (PBGENE-DMD, PBGENE-3243),
CELLECTIS S.A.FrancePublic CompanyAllogeneic CAR-T for hematologic malignancies (BALLI-01, NatHaLi-01, ALPHA3),Gene therapy and non-hematologic oncology (TRAVERSE, Melanoma, other gene-editing programs),Platform technologies, collaborations, and other R&D-related revenue,
REGENERON PHARMACEUTICALS, INC.United StatesPublic CompanyEYLEA franchise (incl. 8 mg),Dupixent (atopic dermatitis, asthma, other type 2 diseases),Oncology (Libtayo and emerging bispecifics),
TAKARA BIO INC.JapanPrivate CompanyGenetic and cellular research reagents,Instruments (PCR and cellular analysis devices),In vitro diagnostics (COVID-19 and related),

EPPENDORF AG

Eppendorf AG is a German private company founded in 1945 that employs 4,358 people. The company specializes in laboratory equipment and life sciences solutions.

ILLUMINA INC

Illumina Inc. is a publicly traded U.S. company founded in 1998 with 8,625 employees. It is a leading provider of DNA sequencing and genetic analysis technologies.

CALYXT

Calyxt is a publicly traded U.S. company founded in 2010 with 118 employees. The company focuses on plant biotechnology and gene-edited crop development.

MAXCYTE, INC

MaxCyte, Inc. is a publicly traded U.S. company founded in 1998 with 91 employees. It develops cell engineering technologies for therapeutic applications.

BECKMAN COULTER

Beckman Coulter is a private U.S. company founded in 1935 with 11,900 employees. It manufactures laboratory instruments and diagnostic equipment for life sciences research.

TAKEDA PHARMACEUTICAL COMPANY

Takeda Pharmaceutical Company is a publicly traded Japanese pharmaceutical company founded in 1781 with 47,029 employees. It is one of the world's largest pharmaceutical manufacturers.

DANAHER CORPORATION

Danaher Corporation is a publicly traded U.S. company founded in 1969 with 59,000 employees. It operates a diversified portfolio of businesses in diagnostics, life sciences, and environmental solutions.

REVVITY, INC.

Revvity, Inc. is a publicly traded U.S. company founded in 1937 with 11,000 employees. It provides analytical technologies and solutions for life sciences and diagnostics.

THERMO FISHER SCIENTIFIC INC.

Thermo Fisher Scientific Inc. is a publicly traded U.S. company founded in 1956 with 125,000 employees. It is a global leader in serving science with laboratory equipment, reagents, and analytical instruments.

MERCK KGAA

Merck KGaA is a publicly traded German company founded in 1668 with 59,077 employees. It operates in pharmaceuticals, life sciences, and performance materials sectors.

GENSCRIPT

GenScript is a publicly traded company based in Hong Kong, founded in 2002 with 6,165 employees. It provides biotechnology services including gene synthesis, protein production, and antibody development.

AGILENT TECHNOLOGIES, INC.

Agilent Technologies, Inc. is a publicly traded U.S. company founded in 1999 with 18,000 employees. It manufactures analytical instruments and laboratory equipment for life sciences and diagnostics.

LONZA

Lonza is a publicly traded Swiss company founded in 1897 with 20,000 employees. It provides contract manufacturing and life sciences solutions for pharmaceuticals and biotechnology.

SANGAMO THERAPEUTICS

Sangamo Therapeutics is a publicly traded U.S. company founded in 1995 with 142 employees. It develops gene therapy and cell therapy treatments using zinc finger protein technology.

PRECISION BIOSCIENCES

Precision Biosciences is a publicly traded U.S. company founded in 2006 with 66 employees. It develops gene-editing therapies using its proprietary genome editing platform.

CELLECTIS S.A.

Cellectis S.A. is a publicly traded French company founded in 1999 with 227 employees. It develops immunotherapy treatments using gene-edited cell technologies.

REGENERON PHARMACEUTICALS, INC.

Regeneron Pharmaceuticals, Inc. is a publicly traded U.S. company founded in 1988 with 15,343 employees. It discovers, develops, and commercializes medicines for serious medical conditions.

TAKARA BIO INC.

Takara Bio Inc. is a private Japanese company founded in 2002 with 1,779 employees. It develops and manufactures biotechnology products and services for life sciences research.

Reasons to Buy this Report

  • Market Size & Growth Validation : Obtain precise US market valuation ($643.3M in 2024) and verified forecast data ($1,026.7M by 2029) to support investment decisions, business planning, and competitive positioning in the American gene editing sector.
  • Regulatory & Clinical Landscape : Understand FDA approval pathways, breakthrough designation programs, and clinical trial pipelines specific to the US market to identify commercialization timelines and market entry opportunities for gene editing therapies.
  • Competitive Intelligence : Analyze leading US biotech and pharmaceutical players, their R&D investments, partnership strategies, and market share to benchmark performance and identify acquisition or collaboration targets.
  • Investment & Funding Trends : Access data on venture capital flows, government R&D funding, and private equity activity in the US gene editing sector to identify emerging companies and investment hotspots.
  • Therapeutic Application Insights : Evaluate US clinical applications across oncology, rare diseases, and immunotherapy to prioritize development focus areas and understand unmet medical needs driving market demand.

Frequently asked questions

What is the current size of the US gene editing market?

The US gene editing market is valued at $643.3 million in 2024 and is projected to grow to $1,026.7 million by 2029.

What is the growth rate of the US gene editing market?

The US gene editing market is growing at a compound annual growth rate (CAGR) of 9.8% from 2024 to 2029.

What factors are driving growth in the US gene editing market?

Key drivers in the US include rising prevalence of genetic disorders, FDA approvals of gene-edited therapeutics, expanding clinical applications, and significant venture capital investment in biotechnology innovation.

Which gene editing technologies are most prevalent in the US market?

The US market is dominated by CRISPR-Cas9 technology, with growing adoption of base editing and prime editing platforms for therapeutic applications.

How does the US gene editing market compare to global trends?

The US leads global gene editing adoption with a 9.8% CAGR, slightly below the global average of 10.2%, reflecting the US market's maturity and established regulatory pathways.

RESEARCH METHODOLOGY

This study on the gene editing market employed secondary sources, directories, and databases to gather pertinent information. To gather and validate important qualitative and quantitative data and evaluate market growth prospects, in-depth interviews were conducted with many primary respondents including key industry participants, subject-matter experts (SMEs), C-level executives from key market players, and industry consultants. After estimating the gene editing market using several research strategies, the size of the final market was obtained by triangulating data from primary research.

Secondary Research

The secondary sources referred to for this research study include publications from government sources, such as the International Chromosome and Genome Society (ICGS), the National Human Genome Research Institute (NHGRI), the Asia Pacific Society of Human Genetics (APSHG), the Genetics Society of America (GSA), the European Society of Human Genetics (ESHG), Centers for Common Disease Genomics (CDDG), Centre for Cellular & Molecular Biology (CCMB) (India), and the Department of Biotechnology (DBT) (India). Secondary sources include corporate and regulatory filings, such as annual reports, SEC filings, investor presentations, and financial statements; business magazines & research journals; press releases; and trade, business, and professional associations. Secondary data was collected and analyzed to arrive at the overall size of the global gene editing market, which was validated through primary research.

Primary Research

Extensive primary research was conducted after acquiring basic knowledge about the global gene editing market scenario through secondary research. Several primary interviews were conducted with market experts from the supply side, such as C-level and D-level executives, operational managers, marketing & sales managers of key manufacturers, distributors, and channel partners of companies providing gene editing products and services; experts from the demand side, such as personnel from pharmaceutical & biotechnology companies, Academic & research institutes, and CROs & CDMOs. These interviews were conducted across six major regions, including North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa. Approximately 70% and 30% of the primary interviews were conducted with supply-side and demand-side participants, respectively. This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.

The following is a breakdown of the primary respondents:

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

Both top-down and bottom-up approaches were used to estimate and validate the total size of the gene editing market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

Bottom-up Approach

  • The key players in the industry and market have been identified through extensive secondary research.
  • The revenues generated from the gene editing market business of leading players have been determined through primary and secondary research.
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.

Top-down Approach

After arriving at the overall market size from the market size estimation process, the total market was split into several segments and subsegments.

Data Triangulation

To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Market Definition

The gene editing market, as covered within the scope of this report, includes products, technologies, and services that facilitate genetic modifications across various applications. This encompasses reagents and consumables, as well as software and systems for planning, executing, and analyzing gene editing processes. Additionally, the report covers services that utilize gene editing technologies like CRISPR, TALEN, ZFN, and other methods such as Meganucleases, PiggyBac, and Prime Editing, applied in areas like cell line engineering, genome editing, drug discovery, clinical diagnostics, and xenotransplantation. These components serve end users, including pharmaceutical and biotechnology companies involved in therapeutic development, as well as academic and research institutes focused on scientific research.

Stakeholders

  • Manufacturers and distributors of gene editing products and services
  • Pharmaceutical and biotechnology companies
  • Market research and consulting firms
  • R&D centers
  • Researchers and scientists
  • Academic & research institutes
  • CDMOs & CROs
  • Biobanks
  • Diagnostic companies.

Report Objectives

  • To define, describe, segment, and forecast the gene editing market based on offerings, product type, product application, product technology, reagent & consumables technique, product end user, service type, service application, service end user and region
  • To provide detailed information about the factors influencing market growth, such as drivers, restraints, opportunities, and challenges
  • To strategically analyze micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall gene editing market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To forecast the size of the market segments concerning six main regions: North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa.
  • To strategically profile the key players in the global gene editing market and comprehensively analyze their core competencies2 and market rankings.
  • To track and analyze competitive developments, such as product launches, acquisitions, collaborations, expansions, and partnerships in the gene editing market.
  • To profile the key players in the global gene editing market and comprehensively analyze their instruments, reagents, kits, consumables, and services portfolios, market positions, and core competencies
  • To track and analyze competitive developments such as product & service launches, expansions, agreements, and collaborations in the gene editing market
  • To benchmark players within the gene editing market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business and service strategy

 

Get the Full Gene Editing Market Report

Full forecast, segment splits, and company analysis for all Gene Editing Market.

Download Sample Pages Buy Report

METHODOLOGY

Need a Tailored Report?

Customize this report to your needs

Get 10% FREE Customization

Customize This Report
Fact checked
Cite this Research
DMCA.com Protection Status